← 返回

CISH 敲除增强人 T 细胞抗肿瘤活性并降低 PD-1 表达水平

英文原题:Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels.

查看英文原题

Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels.

PubMed 2022/12/17(内容时间) Mol Ther Oncolytics

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肿瘤细胞和免疫抑制性肿瘤微环境通过免疫检查点(包括PD-L1/PD-1轴)抑制T细胞的抗肿瘤活性。细胞因子诱导型含SH2蛋白(CISH)是细胞因子信号传导抑制因子(SOCS)家族成员,可抑制T细胞和自然杀伤(NK)细胞中的JAK-STAT和T细胞受体(TCR)信号传导。

然而,其在T细胞免疫检查点调控中的作用仍不清楚。在本研究中,我们用CRISPR-Cas9敲除T细胞中的CISH,发现T细胞对TCR和细胞因子刺激的敏感性增加。

此外,CISH缺失的CAR-T 细胞表现出更长的存活时间以及更高的细胞因子分泌和抗肿瘤活性。值得注意的是,在体外和体内激活的CISH缺失T细胞中,PD-1表达降低。CISH敲除后,激活T细胞中FBXO38(一种降低PD-1表达的泛素化调节蛋白)水平升高。

因此,本研究揭示了CISH通过抑制FBXO38表达来促进PD-1表达的机制,并提出了一种通过抑制CISH增强CAR-T 细胞治疗疗效的新策略。

展开英文摘要原文

Tumor cells and the immunosuppressive tumor microenvironment suppress the antitumor activity of T cells through immune checkpoints, including the PD-L1/PD-1 axis. Cytokine-inducible SH2-containing protein (CISH), a member of the suppressor of cytokine signaling (SOCS) family, inhibits JAK-STAT and T cell receptor (TCR) signaling in T and natural killer (NK) cells.

However, its role in the regulation of immune checkpoints in T cells remains unclear. In this study, we ablated CISH in T cells with CRISPR-Cas9 and found that the sensitivity of T cells to TCR and cytokine stimulation was increased.

In addition, chimeric antigen receptor T cells with CISH deficiency exhibited longer survival and higher cytokine secretion and antitumor activity.

Notably, PD-1 expression was decreased in activated CISH-deficient T cells in vitro and in vivo . The level of FBXO38, a ubiquitination-regulating protein that reduces PD-1 expression, was elevated in activated T cells after CISH ablation. Hence, this study reveals a mechanism by which CISH promotes PD-1 expression by suppressing the expression of FBXO38 and proposes a new strategy for augmenting the therapeutic effect of CAR-T cells by inhibiting CISH.

论文信息

作者
Lv J、Qin L、Zhao R、Wu D、Wu Z、Zheng D、Li S、Luo M
单位
China-New Zealand Joint Laboratory on Biomedicine and Health, State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, CAS Key Laboratory of Regenerative Biology, GIBH-HKU Guangdong-Hong Kong Stem Cell and Regenerative Medicine Research Centre, GIBH-CUHK Joint Research Laboratory on Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.China
期刊
Molecular therapy oncolytics2023 Mar 16
原文标识
PubMed 36654786 · DOI 10.1016/j.omto.2022.12.003